The global burden and epidemiology of invasive non-typhoidal Salmonella infections. Issue 6 (3rd June 2019)

• Record Type: Journal Article
• Authors: Balasubramanian, Ruchita; Im, Justin; Lee, Jung-Seok; Jeon, Hyon Jin; Mogeni, Ondari D.; Kim, Jerome H.; Rakotozandrindrainy, Raphaël; Baker, Stephen; Marks, Florian
• Is Part Of: Human vaccines & immunotherapeutics. Volume 15:Issue 6(2019)
• Page Start: 1421
• Page End: 1426
• Publication Date: 2019-06-03
• Subjects: iNTS disease -- non-typhoidal Salmonella -- Epidemiology -- Burden -- drug-resistance; Vaccines -- Periodicals; 615.372
• DOI: 10.1080/21645515.2018.1504717
• Languages: English
• ISSNs: 2164-5515

Abstract

ABSTRACT: Invasive non-typhoidal Salmonella (iNTS) disease has emerged as a major public health concern. Yet, understanding of the global burden is incomplete, limited particularly by the breadth of blood culture-based surveillance systems that are able to accurately diagnose the etiology of bacteremia. The accessibility of whole genome sequencing has allowed for genetic characterization of pathogens, shedding light on its evolutionary history and sounding alerts for its future progression. iNTS disease is observed to be a particular threat in sub-Saharan Africa, with a case fatality rate greatly exceeding that of typhoid fever, and commonly affecting infants, young children and immunocompromised adults. While iNTS disease might also be a threat in Asia and Latin America, its burden is not well characterized, primarily owing to the lack of comprehensive reporting in these regions. Drug-resistant Salmonella enterica (S. enterica) serovars (e.g. Typhimurium sequence type 313 (ST313)) have emerged as a potential consequence of sustained antibiotic pressure. Genetic analyses have identified distinguished iNTS disease-causing strains that are particularly virulent in certain human host populations. Effective treatment strategies, including vaccination, are necessary; iNTS vaccines targeting the most common S. enterica serovars, Typhimurium, Enteritidis and Dublin, are currently in early developmental stages. Funding and political support is needed to promote vaccine development and implementation programs to ultimately reduce the threat of iNTS disease in high risk areas.